Advisory board

ImmUniverse has a Scientific and Ethics Advisory Board composed of a Scientific Advisory Board and an Ethics Board. The Scientific Advisory Board includes Dr Claudio Fiocchi (Cleveland Clinic, Ohio USA) and Prof. Werner Müller (Emeritus Professor University of Manchester, UK). The Ethics Board members are Dr Michele Tedeschi (Head of the Clinical Trials Office and Secretariat of the Ethics Committee), Prof. Maria Concetta Fargnoli (Professor of Dermatology and member of the IRB, University of L'Aquila) and Prof. Flavio Caprioli (University of Milan, Professor in the field of Gastroenterology).

  • Dr Claudio Fiocchi

    Dr Claudio Fiocchi

    Dr. Fiocchi obtained his medical degree from the Santa Casa Faculty of Medicine in São Paulo, Brazil, followed by training in internal medicine, immunology and gastroenterology in São Paulo, Baltimore, and Cleveland. Currently Dr. Fiocchi is Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, and a staff member of the Department of Inflammation & Immunity in the Lerner Research Institute and staff member of the Digestive Diseases and Surgery Institute. His lifelong research interest is the pathogenesis of inflammatory bowel disease (IBD), where he has made numerous contributions. Dr. Fiocchi was the first to study cytokines in human intestinal immunity and describe cytokine abnormalities in IBD. He was also the first to report angiogenesis as a novel component of IBD pathogenesis and launched the field of intestinal immune-nonimmune cell interactions, which opened the field of intestinal fibrosis. Dr. Fiocchi was one of the very first investigators to describe fundamental differences between early and late IBD and helped to establish the field of paediatric IBD. His most recent interest is the use of systems biology and network medicine to understand IBD in a more comprehensive fashion. Dr. Fiocchi was privileged to train several investigators from the USA, Europe, Asia and South America, many of whom are now IBD leaders in their own countries.

    Dr. Fiocchi received the Premier Physician Award, CCFA (1991), MERIT Award, NIH, USA (1999), Honorary Membership, Portuguese Society of Gastroenterology (2005), The Clifford and Jane Anthony Chair for Digestive Disease Research and Education (2007), Honorary Foreign Membership, Brazilian National Academy of Medicine (2010), the Henry Janowitz Lifetime Achievement Award in IBD, CCFA (2010), Honorary Membership, Brazilian Federation of Gastroenterology (2011), International Herbert Falk Award, Falk Foundation, Germany (2013), DigestScience Research Award, ECCO (2014), the Truelove Lecture, IOIBD (2017), and the Immunology, Microbiology & Inflammatory Bowel Diseases Section Research Mentor Award of the AGA (2018).

    List of References:

    • DonFiocchi C et al. Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflamma¬tory bowel disease. Gastroenterology 1984; ex enim, auctor id dapibus nec, imperdiet ac magna. Vestibulum
    • Fiocchi C et al. Human intestinal mucosa mononuclear cells exhibit lymphokine activated killer cell activity. Gastroenterology 1985;88:625-637.
    • Kusugami K et al. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991;101:1594-1605.
    • Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, Fiocchi C. Localization of interleukin 1 activity, protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749-758.
    • Matsuura T, West GA, Youngman KR, Klein JS, Fiocchi C. Immune activation genes in inflammatory bowel disease. Gastroenterology 1993;104:448-458.
    • Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997;112:1895-1907.
    • Fiocchi C. Intestinal inflammation: a complex interplay of immune-non immune cell interactions. Am J Physiol Gastrointest Liver Physiol 1997;273: G769-G775.
    • Strong S et al. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 1998;114: 1244-1256.
    • Binion D et al. Acquired increased in leukocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742-1746
    • Musso A, Condon TP, West GA, de la Motte C, Strong SA, Levine AD, Bennett CF, Fiocchi C. Regulation of ICAM-1-mediated fibroblast-T-cell reciprocal interaction: implications for modulation of gut inflammation. Gastroenterology 1999;117:546-556.
    • Lawrance I et al. Ulcerative colitis and Crohn’s disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genetics 2001;10: 445-456.
    • Sturm A et al. p53 acts as a negative regulator of intestinal immunity by delaying the cell cycle kinetics of mucosal T-cells. J Clin Invest 2002;109:1481-1492.
    • Danese S et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124:1249-1264.
    • Sturm A et al. Distinctive cell cycle kinetics underlie the pathogenesis of chronic inflammatory diseases. Gut 2004;53:1624-1631.
    • Ina K et al. Intestinal fibroblast-derived IL-10 increases survival of mucosal T-cells by inhibiting growth factor deprivation- and Fas-mediated apoptosis. J Immunol 2005;175:2000-2009
    • Danese S et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006;130:2060-2073.
    • Kugathasan S et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease Gut 2007;56:1696-1705.
    • de Souza HS et al. Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology 2012;143:1017-26.e9. Epub 2012 Jun 26.
    • Schirbel A et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between microbiota and intestinal angiogenesis. Gastroenterology 2013;144:613-623.e9.
    • D'Alessio S et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest 2014 Sep 2;124(9):3863-78.
    • de Souza HS et al. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:739-749.
    • Fiocchi C et al. What’s new in IBD therapy: an “omics network” approach. Pharmacol Res 2020 Sep;159:104886.
    • Fiocchi C et al. IBD systems biology is here to stay. Inflamm Bowel Dis 2021;27:760-770.
    • Fiocchi C et al. Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - what, why, and how. J Crohn Colitis 2021;15:1410-1430.
  • Prof. Flavio Caprioli

    Prof. Flavio Caprioli

    Prof. Flavio Caprioli is Asscociate Professor of Gastroenterology at the University of Milan, Italy. He graduated in Medicine in 2001, and obtained a specialization in Gastroenterology and Digestive Endoscopy in 2005 at the University of Milan. In 2009, Dr. Caprioli gained a PhD in Gastroenterology, working on molecular mechanisms of mucosal T cell resistance to apoptosis in inflammatory bowel diseases. During his PhD, Dr. Caprioli focused his interest in the field of cellular and molecular immunology, exploring mechanisms of autocrine regulation of the T-cell derived cytokine IL-21 in humans, and assessing the role of IL-21 in inducing naive T cell polarization towards the recently discovered effector Th17 lymphocytes. Moreover, he performed studies on the role of IL-21 as a promoter of systemic and intestinal inflammation, and he contributed to evaluate neutralization of this cytokine as a potential new therapeutic approach in autoimmune-related inflammatory diseases. His main field of expertise include: pre-clinical research (in vivo models of inflammation), mucosal and systemic immunology, translational and clinical research in human inflammatory bowel diseases (IBD), including personalized medicine.

    List of References:

    • Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. “Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases.” J Crohn’s Colitis. 2020 Feb 26:jjaa035. doi: 10.1093/ecco-jcc/jjaa035.
    • Strati F, Pujolassos M, Burrello C, Giuffrè MR, Lattanzi G, Caprioli F, Troisi J, Facciotti F “Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon faecal microbiota transplantation in experimental colitis models” Microbiome. 2021 Feb 6;9(1):39. doi: 10.1186/s40168-020-00991-x.
    • Nizzoli G, Burrello C, Cribiù FM, Lovati G., Ercoli G, Botti F, Trombetta E, Porretti L, Todoerti K, Neri A, Giuffrè MR, Geginat J, Vecchi M, Rescigno M, Paroni M, Facciotti F Caprioli F “Pathogenicity of intestinal Th17 lymphocytes is IFNg-dependent”. J Crohns Colitis. 2018 Jul 30;12(8):981-992. doi: 10.1093/ecco-jcc/jjy051
    • Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, Penna G, Dejana E, Rescigno M. “A gut-vascular barrier controls the systemic dissemination of bacteria” Science. 2015;350:830-4
    • Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. “Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease”. N Engl J Med. 2015;372:1104-13
  • Prof. Maria Concetta Fargnoli

    Prof. Maria Concetta Fargnoli

    Maria Concetta Fargnoli is Full Professor of Dermatology and Chairman of the Department of Dermatology at the University of L’Aquila, Italy. She received her medical degree in 1992 at the University of Rome “Tor Vergata”, completed her residency in Dermatology at the University of L’Aquila in 1998 and started her academic career in 1999. She is the Director of the Laboratory of Molecular Biology in Dermato-Oncology, Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, and Faculty of the PhD Program in Experimental Medicine at the University of L’Aquila.

    Her clinical and experimental research interests include epidemiology and molecular genetics of melanoma and non-melanoma skin cancers, non-invasive diagnostic techniques in dermatology, new therapeutic interventions for inflammatory and neoplastic skin diseases. She is actively involved in conducting clinical trials primarily focusing on non-melanoma skin cancers, psoriasis, and atopic dermatitis.

    She has published 233 peer-reviewed scientific papers, contributed to many book chapters and lectured at national and international meetings. Prof. Fargnoli acts as board member of the Giornale Italiano di Dermatologia e Venereologia, reviewer of international journals on dermatology and genetics and referee for ANVUR (National Agency for the Evaluation of Universities and Research Institutes).

    Prof. Fargnoli has been board member and secretary of the Italian Society of Dermatology (SIDeMaST), coordinator of the Group of Experimental Research and Bioengeneering in Dermatology of SIDeMaST and is currently coordinator of the Scientific Committee of SIDeMaST.

    List of References:

    • Pellegrini C, Raimondi S, Di Nardo L, Ghiorzo P, Menin C, Manganoni MA, et al. Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):213-221. doi: 10.1111/jdv.17735. Epub 2021 Nov 3. PMID: 34664323.
    • Fargnoli MC, Pellegrini C, Piccerillo A, Spallone G, Rocco T, Ventura A, et al. Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e923-e926. doi: 10.1111/jdv.17588. Epub 2021 Aug 21. PMID: 34370346.
    • Maturo MG, Rachakonda S, Heidenreich B, Pellegrini C, Srinivas N, Requena C, et al. Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. Sci Rep. 2020 May 14;10(1):8005. doi:10.1038/s41598-020-65057-2.
    • Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, et al. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet. 2020 May;52(5):494-504. doi: 10.1038/s41588-020-0611-8. Epub 2020 Apr 27. PMID: 32341527; PMCID: PMC7255059.
    • Pellegrini C, Cardelli L, Padova M, Nardo LD, Ciciarelli V, Rocco T, Cipolloni G, et al. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases. Acta Derm Venereol. 2020 Jan 23;100(1):adv00040. doi: 10.2340/00015555-3382.
    • Di Nardo L, Pellegrini C, Di Stefani A, Del Regno L, Sollena P, Piccerillo A. et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. J Eur Acad Dermatol Venereol. 2020 May;34(5):932-941. doi: 10.1111/jdv.16098.
    • Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003.
    • Moscarella E, Pellegrini C, Pampena R, Argenziano G, Manfredini M, Martorelli C, et al. Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas. Exp Dermatol. 2019 Jul;28(7):829-835. doi: 10.1111/exd.13951.
    • Ventura A, Pellegrini C, Cardelli L, Rocco T, Ciciarelli V, Peris K, Fargnoli MC. Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci. 2019 Mar 16;20(6):1333. doi: 10.3390/ijms20061333.
    • Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, et al. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. Lancet Child Adolesc Health. 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7.
    • Stratigos AJ, Fargnoli MC, De Nicolo A, Peris K, Puig S, Soura E, et al. MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the Melanostrum Consortium. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2134-2141. doi: 10.1111/jdv.15208.
    • Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, et al. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet. 2018 Dec 1;27(23):4145-4156. doi: 10.1093/hmg/ddy282.
    • Farina AR, Cappabianca L, Ruggeri P, Gneo L, Pellegrini C, Fargnoli MC, et al. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII. J Exp Clin Cancer Res. 2018 Jun 18;37(1):119. doi: 10.1186/s13046-018-0786-3.
    • Fargnoli MC, Altomare G, Benati E, Borgia F, Broganelli P, Carbone A, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Eur J Dermatol. 2017 Dec 1;27(6):599-608. English. doi: 10.1684/ejd.2017.3126.
    • Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci. 2017 Nov 22;18(11):2485. doi: 10.3390/ijms18112485
    • Pellegrini C, Di Nardo L, Cipolloni G, Martorelli C, De Padova M, Antonini A, et al. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis. J Mol Diagn. 2018 Jan;20(1):110-122. doi: 10.1016/j.jmoldx.2017.10.002.
    • Pellegrini C, Orlandi A, Costanza G, Di Stefani A, Piccioni A, Di Cesare A, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. PLoS One. 2017 Aug 22;12(8):e0183415. doi: 10.1371/journal.pone.0183415.
    • Pellegrini C, Maturo MG, Martorelli C, Suppa M, Antonini A, Kostaki D, Verna L, Landi MT, Peris K, Fargnoli MC. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy. Melanoma Res. 2017 Jun;27(3):258-267. doi: 10.1097/CMR.0000000000000323.
    • Tagliabue E, Fargnoli MC, Gandini S, Maisonneuve P, Liu F, Kayser M, Nijsten T, et al. MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. Br J Cancer. 2015 Jul 14;113(2):354-63. doi: 10.1038/bjc.2015.231.
    • Fargnoli MC, Piccioni A, Neri L, Tambone S, Pellegrini C, Peris K. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1926-32. doi: 10.1111/jdv.13076.
    • Pasquali E, García-Borrón JC, Fargnoli MC, Gandini S, Maisonneuve P, Bagnardi V, et al. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 2015 Feb 1;136(3):618-31. doi: 10.1002/ijc.29018.
    • Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014 May;46(5):482-6. doi: 10.1038/ng.2941.
    • Fargnoli MC, Sera F, Suppa M, Piccolo D, Landi MT, Chiarugi A, et al. Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1768-75. doi: 10.1111/jdv.12411.
    • Fargnoli MC, Suppa M, Micantonio T, Antonini A, Tambone S, Peris K. Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. Br J Dermatol. 2014 Feb;170(2):374-81. doi: 10.1111/bjd.12667.
    • Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571.
    • Spica T, Fargnoli MC, Hetet G, Bertrand G, Formicone F, Descamps V, et al. EDNRB gene variants and melanoma risk in two southern European populations. Clin Exp Dermatol. 2011 Oct;36(7):782-7. doi: 10.1111/j.1365-2230.2011.04062.x.
    • Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer. 2010 May;46(8):1413-20. doi: 10.1016/j.ejca.2010.01.027.
    • Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe D, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008 Oct;128(10):2485-90. doi: 10.1038/jid.2008.67.
    • Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008 Jun 15;122(12):2753-60. doi: 10.1002/ijc.23396.
    • Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat. 2007 May;28(5):495-505. doi: 10.1002/humu.20476.
    • Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther. 2006 May;6(5):657-70. doi: 10.1586/14737140.6.5.657.
    • Fargnoli MC, Altobelli E, Keller G, Chimenti S, Höfler H, Peris K. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res. 2006 Apr;16(2):175-82. doi: 10.1097/01.cmr.0000198454.11580.b5.
    • Fargnoli MC, Spica T, Sera F, Pellacani G, Chiarugi A, Seidenari S, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2006 Jan 18;98(2):144-5; author reply 145-6. doi: 10.1093/jnci/djj025.
    • Fargnoli MC, Piccolo D, Altobelli E, Formicone F, Chimenti S, Peris K. Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A case-control study. Melanoma Res. 2004 Apr;14(2):151-7. doi: 10.1097/00008390-200404000-00013.
    • Fargnoli MC, Chimenti S, Keller G, Höfler H, Peris K. Identification of four novel melanocortin 1 receptor (MC1R) gene variants in a Mediterranean population. Hum Mutat. 2003 Jun;21(6):655. doi: 10.1002/humu.9150.
    • Fargnoli MC, Chimenti S, Keller G, Soyer HP, Dal Pozzo V, Höfler H, et al. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. J Invest Dermatol. 1998 Dec;111(6):1202-6. doi: 10.1046/j.1523-1747.1998.00412.x.
  • Prof. Dr. Werner Muller

    Prof. Dr. Werner Muller

    Werner Muller is best known for the discovery that Interleukin-10 (IL-10) deficiencies in mice leads to inflammatory bowel disease and that the development of the disease is driven by the microflora (1). In the IL-10 research field he developed cell type specific IL-10 and IL-10 receptor deficient mice. In these models he could show that IL-10 acts in a cell type specific manner. For example, macrophage derived IL-10 is important for the control of innate inflammatory response (2) while T cell derived IL-10 is important to control T cell responses (3). He later developed a newly designed stable IL-10 protein linking the two IL-10 monomers to a stable dimmer which is very potent in its biological activity and also allows the development of new IL-10 like proteins (4,5) with the potential to inhibit IL-10 action or to be combined with antibody variable regions in order to mimic the cell type specific action of the IL-10 protein. In the area of systems medicine, he coordinated from 2012 to 2017 the EU consortium SysmedIBD (6) which focused on the dynamics of the NF-kappa B pathway in the development of IBD in patient cohorts. Werner Müller was the inaugural Bill Ford Chair of cellular Immunology a the University of Manchester from 2006 until his retirement 2018. He then joint Miltenyi Biotec as Head of Bioinformatics and is a co-developer of the MACSima system that automatizes cyclic immunfluorescence staining methods (7).

    List of References:

    • (1) Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 75(2), 263-274.
    • (2) Roers, A., Siewe, L., Strittmatter, E., Deckert, M., Schlüter, D., Stenzel, W., ... & Müller, W. (2004). T cell–specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. The Journal of experimental medicine, 200(10), 1289-1297.
    • (3) Siewe, L., Bollati–Fogolin, M., Wickenhauser, C., Krieg, T., Müller, W., & Roers, A. (2006). Interleukin‐10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. European journal of immunology, 36(12), 3248-3255.
    • (4) Minshawi, F., Lanvermann, S., McKenzie, E., Jeffery, R., Couper, K., Papoutsopoulou, S., ... & Muller, W. (2020). The generation of an engineered interleukin-10 protein with improved stability and biological function. Frontiers in immunology, 1794.
    • (5)
    • (6)
    • (7) Kinkhabwala, A., Herbel, C., Pankratz, J., Yushchenko, D. A., Rüberg, S., Praveen, P., ... & Bosio, A. (2022). MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors. Scientific reports, 12(1), 1-16.